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Abstract
Purpose Oesophageal squamous cell carcinoma (ESCC) has a poor prognosis. Advanced tumours are treated with fluoropy-
rimidine/platinum chemotherapy followed by irinotecan or taxane monotherapy, but resistance is common and new treatments 
are needed. Approximately 20% of ESCCs carry copy number gain (CNG) of the epidermal growth factor receptor (EGFR) 
gene. Previous trials show that while anti-EGFR monotherapy benefits biomarker-selected patients with EGFR CNG and/
or high EGFR expression, combining anti-EGFR therapies with platinum fluoropyrimidine chemotherapies is not effective, 
and uncertainty remains regarding the optimal cytotoxic chemotherapy partner for anti-EGFR therapies in ESCC.
Methods The effects of EGFR CNG on fluoropyrimidine/platinum chemotherapy sensitivity in a cohort of gastroesopha-
geal cancer patients (n = 302) was evaluated. Drug combination studies using the EGFR inhibitor gefitinib with cytotoxic 
chemotherapies, docetaxel, cisplatin, oxaliplatin and irinotecan, on cell proliferation and cell death of EGFR CNG ESCC 
cell lines were assessed.
Results EGFR CNG in gastroesophageal cancer patients was associated with improved overall survival following fluo-
ropyrimidine/platinum chemotherapy. However, co-administration of gefitinib and oxaliplatin or cisplatin was frequently 
antagonistic in cell-based assays in EGFR CNG ESCC, whereas the combination of gefitinib with docetaxel or irinotecan 
was more efficacious. Co-administration of gefitinib/docetaxel and sequential administration of docetaxel before gefitinib 
showed synergy, but docetaxel given after gefitinib was antagonistic.
Conclusion Gefitinib/platinum co-administration demonstrated antagonism suggesting a possible explanation for the lack 
of benefit from addition of anti-EGFR therapies to fluoropyrimidine/platinum chemotherapy in trials. Gefitinib/docetaxel 
co-administration demonstrated synergy suggesting taxanes could be the most effective cytotoxic partner for anti-EGFR 
therapies in EGFR CNG-positive ESCC, but careful consideration of drug scheduling is required.
Keywords Gastroesophageal cancer · Gefitinib · EGFR · Docetaxel · Platinum · ESCC · Chemotherapy combinations
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Background
Oesophageal cancer is the sixth most common cause of 
death from cancer globally, and squamous cell carcino-
mas of the oesophagus (ESCC), is the dominant histo-
logical subtype of oesophageal cancer worldwide [1]. 
Patients frequently present with advanced disease and, 
as a result of late stage diagnosis and limited treatment 
options, 5-year survival rates remain low at around 15%. 
Current treatments depend on the tumour stage, co-mor-
bidities and patient performance status; surgery is curative 
in fewer than half of patients and the majority of patients 
receive palliative treatment, including chemotherapy [2]. 
Currently, cytotoxic chemotherapy provides a systemic 
therapy option for palliative treatment of ESCC, but 
there are no licenced targeted therapies or predictive bio-
markers and, therefore, an unmet need for more effective 
approaches [3].
First-line palliative chemotherapy usually involves a 
fluoropyrimidine/platinum combination but, eventually, all 
patients develop progressive disease with some receiving 
second-line treatment with a taxane or irinotecan mono-
therapy [4]. Recently, a study in patients progressing after 
fluoropyrimidine/platinum chemotherapy demonstrated 
that the PD-1 inhibitor nivolumab improved overall sur-
vival compared to taxane monotherapy (ATT RAC TION-3 
trial [5]). Although the progression free survival and the 
proportion of patients responding were similar in both 
groups, the responses to nivolumab were more durable 
but took longer to occur than responses to taxanes. These 
findings highlight the importance of identifying the minor-
ity subgroup of patients who would benefit long-term from 
nivolumab, but, in the short term, taxanes are superior. 
However, the low objective response rate (20%) and poor 
long-term survival with taxanes in this setting, indicates 
that treatment resistance is a major clinical challenge that 
needs to be addressed.
One approach to develop novel therapies is to identify 
and target oncogenic drivers and efforts to characterise 
genome alterations within tumour tissue is now enabling 
the selection of biomarkers for precision medicine targeted 
therapies. Potential drivers of oesophageal tumourigen-
esis include the epidermal growth factor receptor (EGFR). 
Copy number gain is detected in around 20% of tumours 
[6, 7], while EGFR is overexpressed in around 50% of 
ESCC tumours and correlates significantly with tumour 
invasion [6]. Targeting EGFR with EGFR tyrosine kinase 
inhibitors (TKi), such as gefitinib, erlotinib or afatinib, 
inhibits the proliferation of oesophageal cancer cell lines 
in vitro [8, 9], but, clinical trials of EGFR inhibitors in 
oesophageal cancer, including ESCC, have shown mixed 
results. Monotherapy trials in unselected patients with 
EGFR inhibitors indicate that there is an EGFR-driven 
minority ESCC subgroup who gain survival, sympto-
matic control and health-related quality of life benefits 
from EGFR inhibitors [10, 11]. In ESCC, EGFR CNG 
assessed by FISH, and/or EGFR protein over-expression 
have shown promise as predictive biomarkers to identify 
this benefiting subgroup, but needs prospective valida-
tion [3, 7, 12, 13]. Cell line models and patient-derived 
xenografts also demonstrate an EGFR-driven subgroup of 
ESCC sensitive to EGFR inhibitors and characterised by 
EGFR CNG and/or EGFR protein over-expression. How-
ever, even in these biomarker-selected groups, intrinsic 
and acquired resistance to EGFR inhibitors remains signif-
icant [8, 14, 15]. The considerable heterogeneity of EGFR 
CNG and protein over-expression observed in ESCC may 
be a key determinant of resistance [16], with rapid selec-
tion and outgrowth occurring of EGFR CNG and protein 
overexpression-negative tumour cell sub-clones that are 
unresponsive to EGFR inhibitors. This emphasises the 
importance of combining EGFR inhibitors with a therapy 
that is effective against EGFR ‘negative’ sub-clones, and 
ideally one that would also synergise with EGFR inhibi-
tors towards the EGFR ‘positive’ driven sub-clones. To 
address this, a number of clinical trials have investigated 
the combination of EGFR inhibitors and cytotoxic chemo-
therapy. Clinical trials combining EGFR inhibitors and 
platinum/fluoropyrimidine chemotherapy in the advanced 
stage setting or with platinum fluoropyrimidine-based 
concurrent chemoradiotherapy in the curative treatment 
setting, have not shown an incremental benefit [17]. In 
the largest randomised trial in ESCC, in molecularly unse-
lected patients with advanced stage disease, the addition 
of the anti-EGFR monoclonal antibody pantitumumab to 
cisplatin and 5FU chemotherapy did not improve overall 
survival [18]. Similarly, in unselected advanced stage gas-
troesophageal adenocarcinoma (GOA) patients, a negative 
impact on overall survival was observed with addition of 
panitumumab to epirubicin, oxaliplatin and capecitabine 
[19, 20]. Conflicting results have also been reported in 
trials of platinum-based chemotherapy in combination 
with EGFR TKi in non-small cell lung cancer patients 
(NSCLC) [21–23]. In contrast, the addition of the EGFR 
TKi erlotinib, to definitive chemoradiotherapy for ESCC, 
which included a taxane (paclitaxel and cisplatin) was 
beneficial [24].
Overall, there is evidence of an EGFR-driven and EGFR 
inhibitor-responsive subgroup of ESCC and, thus, the poten-
tial to combine current standard of care cytotoxic chemo-
therapies with EGFR inhibitors to improve outcomes. The 
development and clinical use of EGFR inhibitors for oesoph-
ageal cancer, however, has been hampered by conflicting 
trial results, which could be a consequence of biomarker-
unselected patient cohorts, and also because questions 
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regarding potential antagonistic effects of co-administration 
of EGFR inhibitors with cytotoxic chemotherapy have been 
raised [25–28]. Furthermore, the clinical relevance of this 
is increased by findings which suggest that, consistent with 
observation in other tumour types, EGFR signalling is a key 
determinant of resistance to immune checkpoint inhibitors in 
ESCC [29], and accordingly EGFR-driven ESCC are likely 
to be a subgroup that derive less, or no, benefit from immune 
checkpoint inhibitors.
To address this, and to identify the drug combinations 
most likely to benefit ESCC patients, in this study, we have 
investigated the outcomes from platinum/fluoropyrimidine 
chemotherapy in EGFR CNG positive and negative gastroe-
sophageal cancer patients and then the combinatorial activ-
ity of EGFR inhibitors with cytotoxic drugs in ESCC cell 
lines with EGFR CNG and varying intrinsic sensitivity to 
gefitinib. Cytotoxic drugs included platinum-based chemo-
therapies (cisplatin and oxaliplatin), a taxane (docetaxel) and 
a topoisomerase inhibitor (irinotecan) which were tested in 
concurrent and sequential administration settings.
Methods
Patients and tumour samples
EGFR FISH was performed, to classify tumours as EGFR 
copy number gain (CNG) positive with either high poly-
somy (defined as having EGFR copy number ≥ 4 in ≥ 40% 
of cells) or gene amplification (defined by presence of tight 
gene clusters and a ratio of gene/chromosome per cell ≥ 2, 
or ≥ 15 copies of the genes per cell in ≥ 10% of analysed 
cells) or EGFR CNG negative (EGFR disomy, low trisomy, 
high trisomy and low polysomy) as described previously [16, 
30], on formalin-fixed paraffin embedded tumour samples 
from the following patient cohorts (Table 1). First, a con-
secutive cohort of 52 patients with advanced stage (TNM 
version 7), gastroesophageal cancer treated with platinum/
fluoropyrimidine-based palliative chemotherapy in 2015 
at Tayside Cancer Centre (Table 1); all patients received 
up to 6 cycles of epirubicin 50 mg/m2 intravenously, day 1 
cisplatin 60 mg/m2 or oxaliplatin 130 mg/m2 intravenously 
on day 1, plus capecitabine 1250 mg/m2 orally days 1–21 
as 2 divided doses, or a continuous intravenous infusion 
of 5-fluorouracil 200 mg/m2/24 h, days 1–21 on a 21 day 
cycle. Secondly, a consecutive cohort of 250 patients with 
operable gastroesophageal cancer (TNM version 7) treated 
with surgical resection ± perioperative chemotherapy with 
3 cycles before surgery and 3 cycles after surgery of: epiru-
bicin 50 mg/m2 intravenously on day 1, cisplatin 60 mg/m2 
intravenously on day 1, plus capecitabine 1250 mg/m2 orally 
days 1–21 as 2 divided doses, or a continuous intravenous 
infusion of 5-fluorouracil 200 mg/m2/24 h on days 1–21 on a 
21-day cycle (Table 1) between 2004 and 2009 in Ninewells 
Hospital Dundee or Aberdeen Royal Infirmary. The use of 
all tumour specimens and clinical data was consistent with 
the patient consent provided and was approved by the appro-
priate UK regional research ethics committees prior to the 
work being undertaken.
Cell lines
Human KYSE520, OE21, and TE8 oesophageal squamous 
carcinoma cells (ESCC) with 14, 14, and 11 EGFR CNG, 
respectively, were obtained from the Cell Resource Center 
for Biomedical Research, Institute of Development, Aging 
and Cancer, Tohoku University, Japan. The cell lines were 
passaged in Roswell Park Memorial Institute RPMI medium 
1640 supplemented with l-glutamine (GIBCO) and 10% foe-
tal bovine serum (FBS) (GIBCO). Cells were tested negative 
for mycoplasma by the in-house testing facility (Mycoalert) 
and were authenticated by STR profiling (NorthGene Ltd, 
Newcastle UK).
Reagents
Stock solutions were prepared as follows: Gefitinib (Iressa) 
(Tocris), 20 mM in DMSO; cisplatin [cis-Diamineplatinum 
(II) dichloride, (Sigma Adrich), 3 mM in sterile PBS; oxali-
platin (Selleckchem), 10 mM in sterile water; docetaxel 
(Selleckchem), 20 µM in DMSO and irinotecan (Tocris) 
(SN-38—active metabolite of CPT-11)], 20 mM in DMSO.
Cell proliferation assays
1000 (OE21, KYSE520, and TE8) viable cells/well were 
seeded overnight in 96-well plates. Cells were then treated 
with either solvent control or two or fourfold dilutions 
of gefitinib, docetaxel, cisplatin, oxaliplatin or SN-38 
(active metabolite of irinotecan). Where possible, drug 
titrations used were selected to be within the range of 
reported peak plasma concentrations of each drug which 
are: gefitinib—1–1.4 µM [31], oxaliplatin—3.6 µM [32], 
cisplatin—165 µM [33], docetaxel—4 µM [34], SN-38—
0.03–0.17 µM [35]. The relative insolubility of cisplatin in 
PBS restricted its maximum working concentration (40 µM) 
to below peak plasma levels. Proliferation assay endpoints 
(control wells 80% confluent during log-phase growth) were 
analysed by CellTitre-Glo® luminescent cell viability assay 
(Promega) according to the manufacturers’ instructions.
Spheroid assays
Microtitre plates (TPP, U-bottomed) were coated with 0.5% 
poly(2-hydroxyethyl methacrylate) (poly-HEMA) pre-
pared in 95% ethanol (two applications of 50 µL dried at 
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37 °C) and were stored at 4 °C until required. TE8 cells 
(1000 cells/100µL in growth media) were seeded into the 
poly-HEMA coated plates and were centrifuged for 10 min, 
2000 rpm. After overnight incubation, tumour cell aggre-
gates/spheroids were treated with 100 µL of the appropriate 
drug concentrations for 5 days before analysis by CellTitre-
glo® assay.
Colony formation assay
OE21 cells were seeded overnight at 1000 cells/well in 
the middle wells of 24-well plates to avoid edge effects, 
before being treated with appropriate drug concentrations. 
Docetaxel and gefitinib monotherapy doses were selected 
to induce approximately 50% reduction in colony number. 
After seven days media was removed, colonies washed in 
PBS, and then fixed in methanol for 30 min. Plates were 
washed, air dried and colonies stained with crystal violet 
staining solution (0.5%w/v in 20% methanol). Excess stain 
was washed off with water, and the plates air-dried before 
scanning. Stained colonies were quantified by solubilisa-
tion in 1% SDS, and the absorbance of the resulting solu-
tion measured at 570 nm.
Table 1  Clinical features of patients tested for epidermal growth factor receptor (EGFR) copy number gain (CNG)
(a) Neoadjuvant cohort
Clinical feature EGFR copy number gain (N = 40) EGFR no copy number gain (N = 109) p
Age, mean (SD) 64.3 (10.1) 64.9 (9.4) 0.733
Sex, no. (%)
 Male
 Female
25 (62.5%)
15 (37.5%)
72 (66%)
37 (37%)
0.687
Histological diagnosis, no. (%)
 Squamous
 Adenocarcinoma
 Other
8 (20%)
31 (77.5%)
1 (2.5%)
18 (16.6%)
83 (76.1%)
8 (7.3%)
0.51
Disease site, no. (%)
 Oesophageal
 Junctional
 Gastric
23 (57.5%)
1 (2.5%)
16 (40%)
53 (48.6%)
16 (14.7%)
40 (36.7%)
0.114
Stage, no. (%)
 I
 II
 III
 IV
7 (17.5%)
11 (27.5%)
20 (50%)
2 (5%)
19 (17.4%)
34 (31.2%)
53 (48.6%)
3 (2.8%)
0.90
Neoadjuvant chemotherapy, no. (%)
 Yes
 No
29 (72.5%)
11 (27.5%)
71 (65.1%)
38 (34.9%)
0.35
(b) Advanced stage cohort
Clinical feature EGFR copy number gain (N = 25) EGFR no copy number gain (N = 27) p
Age, mean (SD) 63.1 (9.6) 59.7 (8.8) 0.191
Sex, no. (%)
 Male
 Female
22 (88%)
3 (12%)
18 (67%)
9 (33%)
0.068
Histological diagnosis, no. (%)
 Squamous
 Adenocarcinoma
 Other
5 (20%)
19 (76%)
1 (4%)
6 (22.2%)
19 (70.3%)
2 (7.4%)
0.84
Disease site, no. (%)
 Oesophageal
 Junctional
 Gastric
19 (76%)
6 (24%)
0 (0%)
19 (70.3%)
8 (29.6%)
0 (0%)
0.647
Stage, no. (%)
 III
 IV
3 (12%)
22 (88%)
6 (22.2%)
21 (77.8%)
0.33
Cancer Chemotherapy and Pharmacology 
1 3
Cell death assays
The proportion of dead cells was determined by CellTox™ 
Green cytotoxicity assay reagent (Promega) by imaging 
prior to, and following, addition of 50µL triton-x aqueous 
permeabilising solution (0.2%); non-viable cells were first 
labelled with CellTox™ Green cytotoxicity assay reagent 
(Promega) (4 µL/mL, 10 µL/well) and monitored during a 
drug treatment time course by  IncuCyte® Zoom real-time 
imaging and software (Essen Biosciences, Sartorius) (first 
reading). The percentage of dead cells was then deter-
mined by permeabilisation/dye-uptake and imaging of 
total cell number (second reading) after triton addition 
and the equation (first reading/second reading)*100.
Drug co‑administration
Studies were designed to conform to the requirements 
outlined for analysis by the Chou–Talalay mathemati-
cal model of drug combinations [36], namely, that com-
bination drugs were used at equimolar dilution ratios at 
predetermined concentrations, where they had an effect 
on cell growth (around the  IC50 values determined by 
prior CellTitre-Glo® cell proliferation assays). Cells were 
seeded at 1000 cells/well in 96-well plates, divided into 
four groups and treated for four days as follows: solvent 
control group; gefitinib alone; cytotoxic drug alone; con-
current group (gefitinib plus cytotoxic). Cell proliferation 
was assessed by CellTitre-Glo® assay.
Sequential drug administration study design
Cells were seeded overnight in 96-well microtitre plates 
and were divided into six groups for treatment for 96-h 
as follows: (1) solvent control group, (2) cytotoxic drug 
alone group—cells were treated continuously with doc-
etaxel, cisplatin or oxaliplatin, (3) gefitinib alone group—
cells were treated continuously with gefitinib, (4) cytotoxic 
drug followed by gefitinib group—cells were incubated 
with docetaxel or cisplatin or oxaliplatin or 48 h followed 
by addition of gefitinib for 48 h, (5) gefitinib followed 
by cytotoxic group—cells were treated with gefitinib for 
48 h followed by addition of docetaxel or cisplatin or 
oxaliplatin for 48 h. (6) Concurrent group (both)—cells 
were incubated concurrently with cytotoxic chemotherapy 
and gefitinib for 96 h. All groups were retreated with the 
appropriate drug dilution on each treatment day and drug 
dilutions in media were balanced for solvent concentra-
tion. No drug washouts were carried out. Cell proliferation 
was assessed by CellTitre-Glo® assay.
Statistical analysis
Survival analysis was performed using IBM SPSS statistics 
v22 (IBM Corporation, Armonk, NY, USA). Kaplan–Meier 
and Cox proportional hazards analysis were used for survival 
analysis and survival time was calculated in days from the 
date of histological diagnosis until the date of death. All 
reported p values are two sided. A p value of < 0.05 was 
considered statistically significant. ANOVA was performed 
using Graphpad prism software.
IC50 values were determined from cell proliferation 
assays using CalcuSyn (Biosoft Version 2.0) or Graphpad 
prism software. The antiproliferative effect of combination 
treatments was evaluated by determining the drug combi-
nation index (CI). Results were analysed according to the 
Chou–Talalay method [36] using CalcuSyn software (Cal-
cuSyn, Inc. Paramus, USA) which generates Dm values 
(IC50), dose response curves and median effect plots. Rec-
ommended symbols for describing synergistic, additive or 
antagonistic effects in drug combination studies analysed 
with the CI method (CalcuSyn user manual) are given where 
appropriate.
Results
EGFR CNG status and outcomes from Platinum/
fluoropyrimidine chemotherapy 
in gastroesophageal cancer patients.
First, we investigated the impact of EGFR signalling on 
clinical chemosensitivity by analysing outcomes in EGFR 
CNG positive and negative gastroesophageal cancer patients 
treated with platinum–fluoropyrimidine combination chemo-
therapy (PBC).
EGFR CNG status was not associated with patient clini-
cal features (Table 1). Analysis of the cohort (n = 52) of 
advanced gastroesophageal cancer patients treated with 
palliative PBC revealed that patients with tumours contain-
ing amplified EGFR (n = 13) had longer median survival 
(315 days, 95% CI 183.3–446.7) than patients without EGFR 
CNG (201 days, 95% CI 184.1–217.9), HR 0.49, 95% CI 
0.23–0.99, p = 0.041 (Fig. 1a). Shorter survival times com-
pared to amplified EGFR cases, were also noted in patients 
with high polysomy (defined as having EGFR copy num-
ber ≥ 4 in ≥ 40% of cells) [16] (Fig. 1b).
Operable patients with EGFR CNG positive tumours 
(high polysomy or amplification) had shorter median over-
all survival (284 days, 95% CI 284.5–737.5) than patients 
with EGFR CNG negative tumours (905  days 95% CI 
566.9–1243.1), HR 1.51, 95% CI 1.09–2.12, p = 0.016). 
However, when analysed according to treatment received 
in this cohort, patients with EGFR CNG positive tumours 
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who received neoadjuvant PBC had longer overall survival 
than patients with EGFR CNG positive tumours who did 
not receive neoadjuvant PBC (Fig. 1c). Patients without 
EGFR CNG positive tumours had similar overall survival 
regardless of whether they received pre-operative PBC or 
not (Fig. 1c). EGFR CNG positive patients who received 
neoadjuvant PBC had similar overall survival to those with-
out EGFR CNG, but EGFR CNG positive patients who did 
not receive neoadjuvant PBC had shorter overall survival 
(Fig. 1c).
Overall, this suggests that gastroesophageal cancer 
patients with EGFR-driven tumours (as identified by EGFR 
CNG) benefit from, and are more sensitive to, PBC. This 
implies that therapeutic inhibition of EGFR-oncogenic 
pathways in EGFR CNG positive patients could negatively 
impact on the expected benefit derived from platinum-based 
chemotherapy and would be antagonistic. These observa-
tions could provide an explanation for negative clinical tri-
als investigating PBC combined with EGFR inhibitors in 
gastroesophageal cancer.
Combinations of gefitinib and cytotoxic 
chemotherapy in EGFR CNG ESCC cell lines
No gastroesophageal adenocarcinoma cell lines with EGFR 
CNG are available, so to investigate the potential antago-
nistic interaction between EGFR inhibitors and oxalipl-
atin and cisplatin, our subsequent experiments focused on 
ESCC. Three ESCC cell lines with EGFR copy number gain 
were selected. KYSE520 cells were considered resistant to 
Fig. 1  EGFR copy number status and outcome following treatment 
with platinum-based chemotherapy in gastroesophageal cancers. 
a Advanced stage patients (n = 52) treated with palliative platinum-
based combination chemotherapy categorised as EGFR amplified and 
EGFR non-amplified. b Advanced stage patients treated with pallia-
tive platinum-based combination chemotherapy categorised as EGFR 
amplified, EGFR high polysomy or EGFR copy number gain negative 
(CNG negative includes EGFR disomy, low trisomy, high trisomy 
and low polysomy). c Operable gastroesophageal cancers treated 
with surgical resection alone or platinum-based neo-adjuvant chemo-
therapy (NACT) followed by surgical resection categorised as EGFR 
copy number gain positive (CNG positive, includes EGFR amplifica-
tion and high polysomy), or EGFR CNG negative
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gefitinib, having an IC50 at around the peak plasma lev-
els (Fig. 2a), while inhibition of proliferation of OE21 and 
TE8 cells occurred at IC50s of 30-fold and fivefold lower 
than peak plasma levels, respectively (Fig. 2b). This range 
in sensitivity to gefitinib reflected the range in response seen 
in patients in the clinical setting. We also determined the 
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Fig. 2  Sensitivity of ESCC cell lines to gefitinib and cytotoxic mon-
otherapy. Dose–response curves (a, c) and IC50s (b, d) for gefitinib 
(a, b) and cytotoxic agents, cisplatin, oxaliplatin, docetaxel, and 
irinotecan (c, d) in three EGFR dysregulated ESCC cell lines. a, c 
Cells were seeded overnight in 96-well plates and treated with con-
centrations of gefitinib, docetaxel, cisplatin, oxaliplatin or SN38 
(irinotecan) as indicated. Cells were harvested with CellTitre-Glo® 
assay reagent (Promega) and graphs depict cell proliferation relative 
to solvent control treated cells (set at 100%). The non-linear curve fit 
was generated using Graphpad from at least three independent assays 
(n) as indicated in the graph legend. IC50 values and 95% confidence 
intervals (b, d) were determined using graphpad prism. Peak plasma 
levels are also given for each agent
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sensitivity of these cell lines to oxaliplatin, cisplatin, doc-
etaxel and irinotecan (administered as the active metabolite 
SN38) (Fig. 2c, d). KYSE520 cells were also least sensi-
tive to cytotoxic agents in agreement with genomics of drug 
sensitivity in cancer data (https ://www.cance rrxge ne.org), 
while TE8 and OE21 cells were relatively sensitive (Fig. 2d).
Having determined the dose response of the agents, we 
conducted combination experiments in gefitinib sensitive 
(OE21, TE8) and resistant (KYSE520) cells using drug titra-
tions at equimolar ratios (representative dose responses in 
OE21 and KYSE520 cells are shown in Fig. 3a) and then cal-
culated combination indices using CalcuSyn software based 
on Chou–Talalay methodology. Mean ED75 combination 
indices ± SD from independent experiments are summarised 
in Fig. 3b. Consistent with our hypothesis, platinum-based 
cytotoxic drugs, cisplatin and oxaliplatin, frequently had 
antagonistic activity when used in combination with gefi-
tinib (CI > 1). The level of antagonism varied the with agent 
and cell line. Both cisplatin and oxaliplatin were antagonistic 
in combination with gefitinib in OE21 cells, the line most 
sensitive to gefitinib as a monotherapy. SN38 combined with 
gefitinib induced responses ranging from nearly additive to 
synergistic. This observation is consistent with reports of 
synergistic interactions between irinotecan and gefitinib in 
colorectal cancer cell lines [37]. Docetaxel plus gefitinib, 
however, consistently showed synergistic activity across the 
cell line panel, and was highly effective at inhibiting the 
proliferation of the previously gefitinib refractory cell line 
KYSE520. Importantly, the combination of gefitinib with 
docetaxel led to dose reduction indices (DRI) for gefitinib 
(ED50, range 2.3–5 fold; ED75 range 3.3–13.7 fold) and 
docetaxel (ED50, range 3.1–8.2 fold; ED75 range 1.8–8 
fold) across the cell line panel (Fig. 3b). These data suggest 
that similar efficacy can be achieved using reduced doses of 
gefitinib and docetaxel when used in combination.
We next tested docetaxel and gefitinib as monother-
apy and combination therapy in kinetic cell death assays 
in OE21 and KYSE520 cells over increasing doses (dose 
1–4) (Fig. 4). As expected, gefitinib induced little cell death 
over the 4-day time course in line with its primary mode 
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Fig. 3  Dose response curves of gefitinib co-administration with 
cytotoxic chemotherapies. a Gefitinib sensitive (OE21) and gefitinib 
resistant (KYSE520) cells were treated with gefitinib alone, cytotoxic 
chemotherapy alone or equimolar titrations of both drugs (combina-
tion). Cell proliferation was determined by CellTitre-Glo® assay, and 
representative graphs depict proliferation relative to solvent control 
treated cells (set at 100%). b Table of combination indices (CI) and 
dose reduction indices (DRI) of gefitinib and cytotoxic chemothera-
pies in ESCC cell lines. Average (± SD) CI values at ED75 deter-
mined by CalcuSyn software from at least three (n) independent 
assays [representative dose response curves are shown in a]. CI val-
ues < 1 indicate synergistic interactions, CI = 1 additive, CI values > 1 
indicate antagonistic interactions. CalcuSyn recommended symbols 
are also provided to indicate the degree of the effect: antagonistic 
(– –  –); moderate antagonism (–  –); slight antagonism (−); nearly 
additive (±); moderate synergism (++); synergism (+++). Mean 
(± SD) DRI determined from independent 96-h assays (n) of gefitinib 
in combination with docetaxel evaluated by endpoint CellTitre-Glo®. 
DRI were calculated by CalcuSyn software. Fa = fraction affected 
equivalent to ED50 and ED75 at 0.5 and 0.75, respectively
Cancer Chemotherapy and Pharmacology 
1 3
of action being induction of  G1 cell cycle arrest. Docetaxel 
induced dose-dependent increases in cell death in both cell 
lines. When docetaxel and gefitinib were used in combina-
tion, synergistic levels of cell death were induced (Fig. 4c, 
d) and with more rapid kinetics (Fig. 4a). In addition, we 
tested responses to gefitinib and docetaxel in 3-D cell aggre-
gates/spheroids and 2D colony formation, which can more 
closely model aspects of in vivo tumour biology such as 
reduced proliferation rates with increased survival, cell: cell 
adhesions, hypoxic cores and long term replicative capacity 
(colony formation). Gefitinib and docetaxel displayed syner-
gistic activity against TE8 cell spheroids at ED50 and ED75 
(Fig. 4e) (CI ED50, 0.15 ± 0.11; ED75, 0.4 ± 0.25. n = 3). 
OE21 and KYSE520 cells did not survive for the duration 
of the 5-day spheroid assay so we were unable to use these 
cells; however, OE21 cells were able to form discrete 2-D 
colonies in colony formation assays and OE21 colonies were 
more significantly inhibited by the combination of gefitinib 
and docetaxel than either drug as a monotherapy (n = 4). 
These results indicated that gefitinib in combination with 
docetaxel had the most consistent activity in ESCC inducing 
synergistic effects on proliferation and cell death in 2-D and 
3-D model systems.
To determine whether synergistic effects could be affected 
by dosing schedules we tested gefitinib and docetaxel in 
sequential treatments over 96  h, D—G = docetaxel fol-
lowed by gefitinib; G—D = gefitinib followed by docetaxel 
and compared the effects on cell proliferation of concurrent 
(combination) gefitinib and docetaxel treatment (Fig. 5). As 
confirmation of our previous results, concurrent administra-
tion of gefitinib and docetaxel induced synergistic inhibition 
of proliferation of all three cell lines. Similar results were 
noted when docetaxel was given prior to gefitinib (sched-
ule D—G). However, there was a striking shift in response 
when gefitinib was given prior to docetaxel (G—D). Admin-
istered sequentially, gefitinib followed by docetaxel was 
antagonistic in all three cell lines, suggesting that careful 
dosing schedules should be devised to avoid deleterious drug 
interactions.
Discussion
Oesophageal squamous cell carcinoma (ESCC) patients 
whose tumours have EGFR CNG and/or EGFR protein 
overexpression may represent a subgroup that benefits from 
EGFR inhibitor monotherapy [7, 12, 13]. However, even in 
this biomarker-selected subgroup of ESCC, significant pro-
portions of patients do not respond to EGFR inhibitors and 
durable responses are uncommon, indicating that primary 
and acquired clinical resistance is a major clinical challenge. 
Heterogeneity is a predominant feature of ESCC, includ-
ing for EGFR CNG and protein over-expression. Tumours 
with a higher number of genomic clonal subpopulations that 
are not EGFR-driven are less likely to respond significantly 
to monotherapy with an EGFR inhibitor. Therefore, EGFR 
combination treatments are likely to be important to opti-
mise treatment effectiveness in EGFR CNG positive ESCC.
Several clinical trials have investigated the combina-
tion of EGFR inhibitors with cytotoxic chemotherapy or 
concurrent chemoradiotherapy [17–20, 24]. In the pallia-
tive setting, in both ESCC and GOA, the addition of EGFR 
inhibitors to platinum plus fluoropyrimidine chemotherapy 
has not improved overall survival [18–20]. Similarly, in the 
radical treatment setting, the addition of EGFR inhibitors to 
concurrent chemoradiotherapy, with a platinum and fluo-
ropyrimidine chemotherapy backbone has not improved 
overall survival [17]. However, addition of EGFR inhibi-
tion to chemoradiotherapy in ESCC with a chemotherapy 
backbone incorporating paclitaxel did improve overall sur-
vival, even in biomarker-unselected patients [24]. Consistent 
with these clinical trial results we observed that EGFR CNG 
positive gastroesophageal cancers in both the palliative and 
neoadjuvant setting appear to be more sensitive to platinum 
fluoropyrimidine-based cytotoxic chemotherapy. This sug-
gests that the use of an EGFR inhibitor could reduce, or 
negate, the benefit of platinum-based cytotoxic chemother-
apy in patients with EGFR-driven tumours and would thus 
be antagonistic. We confirmed drug antagonism in EGFR 
CNG cell lines. Because no GOA cell lines with EGFR CNG 
are available, our cell line experiments were restricted to 
ESCC. This is a limitation of our work, and deriving EGFR 
CNG GOA cell lines to confirm our findings would be 
advantageous. The finding of synergy between docetaxel 
and gefitinib observed in 2-D cell culture was supported 
by our findings in longer-term 2-D colony formation assays 
and in 3-D spheroid culture models. However, not all cell 
lines used in this study were able to grow in 3-D culture and 
likewise, to overcome this limitation of the current study, 
testing of additional EGFR CNG positive cell lines that are 
able to survive anchorage-independent seeding would be 
advantageous. Investigation of drug synergy in an in vivo 
xenograft model, evaluation of the impact of EGFR CNG on 
survival in a cohort of ESCC patients treated with docetaxel 
monotherapy, as well as extension of investigation to other 
EGFR inhibitors would also be beneficial. In addition, eluci-
dation of the mechanism of synergy between docetaxel and 
gefitinib, or other EGFR inhibitors, in EGFR CNG positive 
ESCC would also provide additional understanding and may 
suggest predictive biomarkers to identify those patients that 
might benefit most from this combination.
The majority of earlier reports have suggested that EGFR 
protein expression and/or EGFR gene copy number gain 
are associated with shorter survival of gastroesophageal 
cancers including adenocarcinomas and ESCCs [38–40]. 
However, longer survival, or no impact, has been observed 
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in other studies [38–40]. In contrast to our investigation, 
the influence of treatment modality in general and cyto-
toxic chemotherapy in particular on how EGFR impacts the 
clinical outcomes has not been investigated in the major-
ity of these studies. Our data shows an interaction between 
neo-adjuvant PBC and the impact of EGFR and, consistent 
with the findings of previous studies, indicates that the treat-
ment patients receive should be taken into account when the 
impact of EGFR is being considered. Furthermore, Smyth 
et al., reported that higher tumour EGFR RNA expression 
is associated with shorter overall survival in gastroesopha-
geal cancer patients treated with peri-operative PBC [41]. 
These findings contrast with ours, and suggest that EGFR 
copy number measured by FISH and EGFR RNA expression 
measured by nanostring may be measuring different aspects 
of gastroesophageal cancer biology. For example EGFR 
FISH-positive tumours almost invariably overexpress EGFR 
RNA (and EGFR protein), but up to 50% of EGFR FISH-
negative tumours also have high EGFR RNA and protein 
[42, 43]. The lack of benefit from gefitinib in EGFR CNG-
negative patients (which might have still high expression 
EGFR RNA and or protein) suggests that EGFR protein or 
RNA expression may be a less reliable marker of EGFR-
driven gastroesophageal cancers and a less reliable marker of 
the impact of EGFR signalling and EGFR inhibitors on PBC 
sensitivity, resistance or clinical outcomes. Nevertheless, 
these findings also indicate the importance of considering 
the type of EGFR assay used in gastroesophageal predictive 
and prognostic studies. To our knowledge the impact of 
EGFR CNG on overall survival in advanced stage patients 
treated with palliative platinum fluoropyrimidine chemo-
therapy (PBC) has not been previously reported.
Our data indicating that the combination of gefitinib with 
cisplatin is antagonistic (in TE8 and OE21 cells) are at odds 
with reports that treatment of TE8 xenograft tumours with 
cisplatin in combination with EGFR inhibition by cetuxi-
mab significantly reduces their size [44]. Such discrepancies 
may arise due to the nature of the mechanism of inhibition 
of EGFR (small molecule EGFR TKi versus blocking anti-
body with potential antibody-dependent cellular cytotoxicity 
effects). However, clinical results of EGFR monoclonal anti-
bodies both as monotherapy and in combination with PBC in 
ESCC have been similar to those demonstrated with EGFR 
TKis [10, 18, 20–23, 27, 28, 35]. In addition, in line with 
our conclusions, the POWER phase III RCT in advanced 
ESCC did not demonstrate any benefit of the addition of the 
humanised monoclonal anti-EGFR antibody panitumumab 
to cisplatin plus fluoropyrimidine chemotherapy [18]. 
POWER enrolled molecularly unselected ESCC patients, 
but, a retrospective analysis demonstrated that EGFR IHC 
did not correlate significantly with overall survival, and 
EGFR copy number was not investigated. The antagonism 
between cisplatin and oxaliplatin and EGFR inhibition pro-
vides a key explanation for this, and other, negative clini-
cal trials and suggests that, even if these trials had been 
undertaken in biomarker-selected patients, benefit from the 
addition of EGFR inhibitors may not have been observed.
Previous studies in KYSE30 cells have suggested that the 
sequence of administration of gefitinib in combination with 
cytotoxic agents determines efficacy. Synergy was noted 
with cisplatin, carboplatin, oxaliplatin, docetaxel and pacli-
taxel followed by gefitinib [45]. However, our studies in a 
wider cell panel suggest that the effect of concurrent gefitinib 
with platinum-based cytotoxic drugs is cell line-dependent 
and thus the effects of this combination may be unpredict-
able in the clinical setting. In contrast, we demonstrated 
that gefitinib and docetaxel was consistently synergistic. 
This observation is consistent with the demonstration that 
addition of erlotinib to chemoradiotherapy including pacli-
taxel was beneficial in ESCC [24]. In this study there was 
no biomarker selection, and we hypothesise that in this trial 
the greatest benefit from addition of erlotinib will be seen in 
those patients who are EGFR CNG and/or have EGFR pro-
tein overexpression. Our dose reduction analysis indicates 
that equivalent reductions in tumour cell growth could be 
achieved with lower doses of gefitinib and docetaxel if used 
in combination, which could have significant advantages 
in terms of reduced financial costs of the treatment and, 
more critically, reduced toxicity to the patient. The cell line 
studies also suggest that the sequence of administration of 
taxane and EGFR inhibitor is critical. The administration of 
Fig. 4  Docetaxel in combination with gefitinib synergistically 
enhances ESCC cell death. Cytotoxicity of drug treatments (doc-
etaxel alone, gefitinib alone or gefitinib plus docetaxel combina-
tion) on the ESCC cell lines OE21 (a, c) and KYSE520 (b, d) was 
assessed by CellTox™ green assay and imaging  (IncuCyte® Zoom). 
a, b Time course of treatment: cells were treated for 4 days with sol-
vent (control) increasing doses of docetaxel (OE21 and KYSE520: 
dose 1 = 0.3215  nM; dose 2 = 0.625  nM; dose 3 = 1.25  nM; dose 
4 = 2.5  nM), gefitinib (sensitive line OE21: dose 1 = 0.05  µM; dose 
2 = 0.1  µM; dose 3 = 0.2  µM;, dose 4 = 0.4  µM and resistant line 
KYSE520: dose 1 = 1.25 µM; dose 2 = 2.5 µM; dose 3 = 5 µM;, dose 
4 = 10 µM) or both drugs combined (both). c, d Endpoint  IncuCyte® 
data from day 4 are presented as dose response curves in OE21 (c) 
and KYSE520 (d) (mean ± SEM of at least three replicate wells, 4 
fields per well of a representative assay). Synergistic combination 
indices at effective dose 50%, 75% and 90% (ED50, ED75 and ED90) 
are indicated. e Five-day TE8 3-D anchorage independent spheroid 
assays treated with equimolar fourfold dilution series of gefitinib 
(from 8 µM) and docetaxel (from 8 nM) as single agents or in com-
bination. Synergy ED50 and ED75 CI values were calculated using 
CalcuSyn and are presented as the mean CI ± SD from three inde-
pendent assays. (ED90s were not reached and calculated CI ED90 
were variable across independent assays). f OE21 colony formation 
assay using docetaxel and gefitinib doses selected to induce approxi-
mately 50% reduction in colony number as a monotherapy, and in 
combination. Statistical comparisons were performed using Graphpad 
prism software (ANOVA plus Bonferroni correction for multiple test-
ing from n = 4 independent assays; *p = 0.01–0.05, **p = 0.001–0.01, 
***p =  < 0.001)
◂
 Cancer Chemotherapy and Pharmacology
1 3
OE21
synergism antagonism
KYSE520
-1.5 -1 -0.5 0 0.5 1 1.5 2 2.5 3 3.5 4TE8
ED50
ED75
ED90
ED50
ED75
ED90
ED50
ED75
ED90
0 0.012 0.025 0.05 0.1 0.2 0.4
0
20
40
60
80
100
120
0 0.08 0.16 0.31 0.63 1.25 2.5
Gefinib Concentraon (µM)
%
 o
f c
on
tr
ol
Docetaxel Concentraon (nM)
Gefinib
Docetaxel
Both
G-D
D-G
0 0.31 0.63 1.25 2.5 5 10
0
20
40
60
80
100
120
0 0.16 0.31 0.63 1.25 2.5 5
Gefinib Concentraon (µM)
%
 o
f c
on
tr
ol
Docetaxel Concentraon (nM)
Gefinib
Docetaxel
G-D
D-G
Both
c
d
a b
0 0.04 0.08 0.16 0.31 0.63 1.25
0
20
40
60
80
100
120
0 0.04 0.08 0.16 0.31 0.63 1.25
Gefinib Concentraon (µM)
%
 o
f c
on
tr
ol
Docetaxel Concentraon (nM)
Gefinib
Docetaxel
G-D
D-G
Both
Cancer Chemotherapy and Pharmacology 
1 3
gefitinib prior to docetaxel invariably resulted in antagonism 
which is consistent with studies in both an NSCLC cell line 
[46] and in KYSE30 ESCC cells [45]. This data suggests 
that careful scheduling, or drug holidays may be required 
to avoid possible antagonistic drug interactions. In support 
of this, when used in combination with paclitaxel, pulsatile 
administration of gefitinib has proved more effective than 
continuous dosing in murine models of breast cancer, [47].
The molecular mechanism of drug combination antago-
nism or synergy in this setting is unclear and is under inves-
tigation. In vitro studies analysing potential combination 
therapies on both head and neck SCC and NSCLC cell lines 
suggest that there is also antagonism between gefitinib and 
cisplatin in other tumour types [25–27]; the effects have 
been variously attributed to cisplatin cytotoxicity being 
dependent on EGFR phosphorylation and degradation [28], 
induction of epithelial to mesenchymal transition (EMT) 
which is associated with increased resistance to gefitinib 
[26], reduced cisplatin entry into the cell and increased 
DNA repair or cell cycle arrest in  G1. However, antagonism 
can be overcome by concurrent use of autophagy inhibi-
tors (without any apparent effect on the cell cycle) [27] sug-
gesting that factors other than the phase of the cell cycle 
may be involved. Previous reports in colorectal cancer cells 
have suggested that treatment of cells with cytotoxic agents 
increases phosphorylation of EGFR rendering cells more 
sensitive to the effects of EGFR TKis, whereas antagonistic 
interactions result from a cytotoxic drug induced a decrease 
in EGFR phosphorylation [37, 48]. In NSCLC, the mecha-
nism of synergistic interaction was also suggested to be due 
to increased docetaxel-induced phosphorylation of EGFR 
and its subsequent inhibition following gefitinib addition 
[6]; however, similar analysis of our ESCC cell lines over 
several repeat experiments was inconclusive. The antago-
nistic effect of sequential administration of gefitinib prior to 
docetaxel could be due to cell cycle effects, where gefitinib 
induces a G1 cell cycle arrest thus rendering taxanes (which 
are primarily mitotic spindle inhibitors acting in G2/M) inef-
fective [45, 46]. Since concurrent administration of gefitinib 
or administration after docetaxel is synergistic, in the clinic, 
this would suggest that an interrupted schedule of an oral 
TKi like gefitinib, might be needed in combination with 
a taxane. Alternatively, and in contrast to common clini-
cal practice at present, an anti-EGFR monoclonal antibody 
should potentially be administered after docetaxel and not 
before, when combined with a taxane.
Recently, the ATT RAC TION-3 study demonstrated that 
the PD-1 inhibitor nivolumab provided improved overall 
survival compared to taxane monotherapy suggesting that 
nivolumab is a new standard of care for ESCC after pro-
gression with fluoropyrimidine/platinum chemotherapy [5]. 
However, given that only a minority subgroup of patients 
respond to nivolumab and responses took a median of 
2.6 months to occur, its use presents clinical challenges in 
this setting, where patients often have high tumour burdens 
and are very symptomatic. In addition, in squamous cell 
carcinomas including ESCC, EGFR activation is associated 
with depleted tumour infiltrating lymphocytes and resistance 
to immune checkpoint inhibition (ICI) [29]. EGFR activa-
tion leads to increased anaerobic glycolysis in tumour cells, 
glucose depletion and accumulation of lactate in squamous 
cell carcinomas, meaning that tumour-infiltrating T cells, 
may have to compete for metabolic fuels. ICI appear to be 
less effective in EGFR mutant positive NSCLC [29, 49], and 
EGFR activation has been associated with hyper-progression 
following ICI therapy [50]. Early phase trials in NSCLC 
have revealed problematic toxicity combining EGFR inhibi-
tors and immune checkpoint inhibitors [51]. Together these 
data suggest that EGFR-driven ESCC, identified by EGFR 
CNG and /or EGFR protein overexpression are likely to be 
less sensitive to nivolumab which is unlikely as a mono-
therapy to provide an effective treatment for this group of 
patients. As such, taxanes will likely remain one standard 
of care for ESCC after progression with fluoropyrimidine/
platinum chemotherapy, either before or after nivolumab. 
Overall, our results contribute additional evidence to support 
investigation of EGFR inhibitors in EGFR CNG positive 
ESCC and suggest that a combination strategy with taxanes 
has the potential for synergism thereby optimising clinical 
impact and effectiveness. Since taxanes are a standard of 
care for ESCC after progression with fluoropyrimidine/plati-
num chemotherapy evaluating the benefit of the addition 
of an EGFR inhibitor to docetaxel or paclitaxel in tumours 
that are EGFR CNG and/or EGFR protein overexpressed by 
IHC would be the most appropriate initial area of clinical 
investigation.
In summary, drug combination studies indicate that tar-
geting EGFR in ESCC cells carrying EGFR copy number 
gain may negate or reduce anticancer effects of platinum-
based chemotherapy; however, EGFR inhibitors are effica-
cious and synergistic in combination with docetaxel when 
scheduled correctly. We recommend further preclinical 
studies and consideration of clinical investigation of sched-
uled anti-EGFR therapies combined with taxanes for ESCC 
Fig. 5  Efficacy of docetaxel/gefitinib combination treatment is 
sequence-dependent. a–c Representative dose response curves of 
gefitinib sensitive OE21 (a), gefitinib resistant KYSE520 (b) and 
gefitinib sensitive TE8 (c) ESCC cells were treated for 4  days with 
gefitinib or docetaxel and both drugs either in combination or sequen-
tially: 4 days both drugs (both), 48-h gefitinib treatment followed by 
addition of docetaxel for the remaining 48-h (G—D) or 48-h doc-
etaxel treatment followed by addition of gefitinib for the remaining 
48 h (D—G). Cells were analysed by CellTitre-Glo® assay (d)  Log2 
combination indices were determined from assays described in a–c 
using CalcuSyn software, where 0 = additive effects, < 0 = synergistic 
effects, > 0 = antagonistic.  log2 CI values at 50%, 75% and 90% effec-
tive dose ED50, ED75 and ED90, respectively, are displayed
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patients with tumours expressing high EGFR by IHC and/
or EGFR CNG.
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